Wednesday, December 7, 2016

BRIEF-Transgene says UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo

* Transgene: UC Davis to conduct phase 2 trial of the

combination of TG4010 with Opdivo (Nivolumab) for 2nd line

treatment of metastatic non-small cell lung cancer (NSCLC)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)